Entrada Therapeutics (NASDAQ:TRDA) Cut to Sell at Wall Street Zen

Wall Street Zen cut shares of Entrada Therapeutics (NASDAQ:TRDA) from a hold rating to a sell rating in a report issued on Saturday morning.

Separately, HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Entrada Therapeutics in a research report on Tuesday, May 20th. One analyst has rated the stock with a sell rating, three have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $25.67.

Entrada Therapeutics Trading Down 2.4%

Shares of Entrada Therapeutics stock opened at $7.41 on Friday. The business’s 50 day simple moving average is $8.21 and its 200-day simple moving average is $11.79. The stock has a market capitalization of $281.23 million, a price-to-earnings ratio of 4.66 and a beta of -0.06. Entrada Therapeutics has a twelve month low of $7.10 and a twelve month high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.42) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.78) by $0.36. Entrada Therapeutics had a return on equity of 16.11% and a net margin of 25.53%. The business had revenue of $8.75 million for the quarter, compared to analysts’ expectations of $10.98 million. Sell-side analysts predict that Entrada Therapeutics will post 1.12 earnings per share for the current year.

Institutional Trading of Entrada Therapeutics

Several large investors have recently added to or reduced their stakes in TRDA. Charles Schwab Investment Management Inc. increased its position in Entrada Therapeutics by 6.0% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company’s stock valued at $3,408,000 after acquiring an additional 11,143 shares during the period. AlphaQuest LLC acquired a new position in shares of Entrada Therapeutics during the 4th quarter valued at $70,000. American Century Companies Inc. increased its position in shares of Entrada Therapeutics by 17.7% during the 4th quarter. American Century Companies Inc. now owns 59,710 shares of the company’s stock valued at $1,032,000 after purchasing an additional 8,985 shares during the period. KLP Kapitalforvaltning AS acquired a new position in shares of Entrada Therapeutics during the 4th quarter valued at $36,000. Finally, LPL Financial LLC increased its position in shares of Entrada Therapeutics by 12.9% during the 4th quarter. LPL Financial LLC now owns 55,154 shares of the company’s stock valued at $954,000 after purchasing an additional 6,310 shares during the period. 86.39% of the stock is currently owned by institutional investors and hedge funds.

Entrada Therapeutics Company Profile

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.